GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...